Royalty Pharma (RPRX) Cash & Current Investments (2020 - 2026)

Royalty Pharma has reported Cash & Current Investments for 7 years, with the latest figure at $608.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 44.69% year-over-year to $608.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $608.3 million (down 44.69% YoY) and the FY2025 annual result came in at $637.5 million, down 35.43% from the prior year.
• Cash & Current Investments fell to $608.3 million in Q1 2026 per RPRX's latest filing, from $637.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $2.5 billion in Q2 2022 and troughed at $495.3 million in Q4 2023.
• A 5-year average of $1.3 billion and a median of $998.6 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 104.11% in 2022, then tumbled 71.45% in 2023.
• Over 5 years, Cash & Current Investments stood at $1.7 billion in 2022, then tumbled by 71.45% to $495.3 million in 2023, then surged by 99.31% to $987.2 million in 2024, then slumped by 35.43% to $637.5 million in 2025, then decreased by 4.58% to $608.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $608.3 million, $637.5 million, and $955.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.